A prospective cohort study was carried out to evaluate uterine volume and the volume of uterine leiomyomas in women using the levonorgestrel intrauterine system (LNG-IUS) to treat idiopathic menorrhagia (n=32) and menorrhagia due to leiomyomas (n=27). A control group used the device as a contraceptive method (n=28).
Clinical and ultrasonographic evaluations were carried out at insertion and at 3, 6, 12, 24 and 36 months later. Total uterine volume and the volume of the leiomyomas were calculated using the ellipsoid formula (anteroposterior diameter)��(transverse diameter)��(longitudinal diameter)��(4/3)��(��). In the case of multiple leiomyomas, the volume of each myoma was added to calculate the total volume of leiomyomas in each patient. Menstrual bleeding episodes were recorded.
Uterine volume decreased significantly in both groups of menorrhagic patients but not in the control group. In the group of women with idiopathic menorrhagia, a mean reduction of 36.4��15.3 (S.D.) cm3 (from 127.1 cm3 to 90.7 cm3) was observed (p=.041), and a greater and more significant mean reduction of 63.6��19.0 (S.D.) cm3 (from 156.6 cm3 to 93��cm3) occurred in the group of women with leiomyomas (p=.014). In the contraception group, the reduction was of only 2.9��5.4 (S.D.) cm3 in mean uterine volume (from 70.3 cm3 to 67.4 cm3), which was not statistically significant (p=.085). The mean volume of leiomyomas decreased by 5.2��3.1 (S.D.) cm3 (from 12.8 cm3 to 7.6 cm3) after 3 years of use, but this difference was not significant (p=.4099). After 36 months of use, amenorrhea and oligomenorrhea were the most frequent bleeding patterns, occurring in 45���57% and 33���39% of users in the three groups, respectively. Amenorrhea was higher in the contraception group (57.1%) and in women with idiopathic menorrhagia (53.4%) than women in the group with menorrhagia due to leiomyomas (44.5%) (p=.027). Moreover, the prevalence of spotting was almost three times higher (11%) in women with menorrhagia caused by leiomyomas and nearly double (7.7%) in the idiopathic menorrhagia group when compared with 4% in the control contraception group (p=.024).
The LNG-IUS significantly reduces uterine volume in women with menorrhagia with and without leiomyoma; however, it does not significantly reduce the volume of leiomyomas.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Progestin-releasing intrauterine systems.Semin Reprod Med. 2001; 19: 355-363
- The levonorgestrel intrauterine system: therapeutic aspects.Steroids. 2000; 65: 699-702
- A Latin American experience with levonorgestrel IUD.Ann Med. 1993; 25: 149-153
- Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study (1).Contraception. 2002; 65: 325-328
- Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.Cochrane Database Syst Rev. 2005; 19: CD002126
- Use of a levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas.J Reprod Med. 2005; 50: 613-617
- Noncontraceptive health benefits of intrauterine devices: a systematic review.Obstet Gynecol Surv. 2002; 57: 120-128
- Successful treatment of fibroids using an intrauterine progesterone device.Int J Gynaecol Obstet. 1994; 46: 55
- Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas.Fertil Steril. 2003; 79: 1194-1198
- Clinical outcomes and costs with levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.JAMA. 2004; 291: 1456-1463
- Effects of progesterone on uterine leiomyoma growth and apoptosis.Steroids. 2000; 65: 585-592
- Value of sonography in the diagnosis of abnormal vaginal bleeding.J Clin Ultrasound. 2004; 32: 348-353
- Clinical gynecologic endocrinology and infertility.7th ed. Lippincott Williams & Wilkins, Philadelphia2005
- Insulin-like growth factor (IGF), IGF binding protein (IGFBP) and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata.Hum Reprod. 1993; 8: 1796-1806
- Correlation between endometrial histology, microvascular density and calibre, matrix metalloproteinase-3 and bleeding pattern in women using a levonorgestrel-releasing intrauterine system.Hum Reprod. 2004; 19: 1778-1784
Published online: January 17, 2007
Accepted: November 14, 2006
Received in revised form: November 13, 2006
Received: January 24, 2005
���This study received no funding, and each patient paid the costs of her own treatment.
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.